In today’s session Impax Laboratories Inc (IPXL) recorded an unusually high (162) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious IPXL decrease. With 162 contracts traded and 194 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: IPXL161118P00017500 closed last at: $1.3 or 36.8% up. About 1.04M shares traded hands or 5.69% up from the average. Impax Laboratories Inc (NASDAQ:IPXL) has declined 59.78% since April 8, 2016 and is downtrending. It has underperformed by 65.43% the S&P500.
Analysts await Impax Laboratories Inc (NASDAQ:IPXL) to report earnings on November, 14. They expect $0.41 earnings per share, up 2.50% or $0.01 from last year’s $0.4 per share. IPXL’s profit will be $24.10 million for 8.61 P/E if the $0.41 EPS becomes a reality. After $0.21 actual earnings per share reported by Impax Laboratories Inc for the previous quarter, Wall Street now forecasts 95.24% EPS growth.
Impax Laboratories Inc (NASDAQ:IPXL) Ratings Coverage
Out of 12 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 3 rate it a “Buy”, 2 “Sell”, while 7 “Hold”. This means 25% are positive. Impax Laboratories Inc. has been the topic of 18 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The firm has “Sector Perform” rating by RBC Capital Markets given on Tuesday, February 23. The rating was maintained by Leerink Swann on Tuesday, August 11 with “Market Perform”. The rating was initiated by JP Morgan on Wednesday, January 6 with “Neutral”. BTIG Research initiated the stock with “Buy” rating in Tuesday, October 6 report. The rating was maintained by Deutsche Bank with “Hold” on Wednesday, August 10. As per Monday, November 7, the company rating was downgraded by Bank of America. The firm has “Sector Perform” rating by RBC Capital Markets given on Thursday, November 10. On Tuesday, April 19 the stock rating was initiated by Northland Capital with “Market Perform”. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Market Perform” rating by BMO Capital Markets on Wednesday, June 29. The stock of Impax Laboratories Inc (NASDAQ:IPXL) earned “Positive” rating by Susquehanna on Tuesday, July 21.
According to Zacks Investment Research, “Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company engaged in the development, manufacture, and marketing of specialty prescription pharmaceutical products utilizing its own formulation expertise and drug delivery technologies. IMPAX Laboratories is focusing on two key areas, namely Generic Pharmaceutical Products and Branded Pharmaceutical Products. In the generic pharmaceuticals market, it focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system disorders. The company sells its products to large pharmaceutical wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies through strategic alliances and the company’s global pharmaceuticals division.”
Insitutional Activity: The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.11, from 1.28 in 2016Q1. The ratio increased, as 26 funds sold all Impax Laboratories Inc shares owned while 50 reduced positions. 27 funds bought stakes while 79 increased positions. They now own 64.34 million shares or 0.71% less from 64.79 million shares in 2016Q1.
Aperio Grp Inc Limited Liability Co has 0% invested in the company for 12,168 shares. Orbimed Advsrs Ltd Liability holds 5.89M shares or 1.77% of its portfolio. Ls Limited holds 0.01% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL) for 2,920 shares. Guggenheim Limited Liability Company owns 133,531 shares or 0.01% of their US portfolio. Marshall Wace Llp reported 8,729 shares or 0% of all its holdings. Aravt Ltd owns 2.23M shares or 4.78% of their US portfolio. Jpmorgan Chase And has 0% invested in the company for 86,205 shares. Blackrock Invest Management Ltd Company, a New Jersey-based fund reported 303,791 shares. Morgan Stanley holds 0% or 6,440 shares in its portfolio. Capstone Asset reported 23,499 shares or 0.02% of all its holdings. Springbok Cap Management accumulated 0.01% or 3,083 shares. Cornerstone Capital Mngmt Ltd Liability Corporation reported 119,307 shares or 0.03% of all its holdings. Bnp Paribas Arbitrage reported 34,208 shares or 0% of all its holdings. Swiss National Bank owns 103,800 shares or 0% of their US portfolio. Credit Suisse Ag holds 108,237 shares or 0% of its portfolio.
Insider Transactions: Since August 15, 2016, the stock had 0 insider purchases, and 1 insider sale for $230,199 net activity. $230,199 worth of Impax Laboratories Inc (NASDAQ:IPXL) was sold by BENET LESLIE Z.
Impax Laboratories, Inc. is a specialty pharmaceutical company. The company has a market cap of $829.87 million. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products , as well as the development and marketing of branded products. It has a 30.17 P/E ratio. The Company’s divisions include Impax Generics and Impax Specialty Pharma.
IPXL Company Profile
Impax Laboratories, Inc., incorporated on March 23, 1995, is a specialty pharmaceutical company. The Firm is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. The Company’s divisions include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of the Company’s generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
More notable recent Impax Laboratories Inc (NASDAQ:IPXL) news were published by: Businesswire.com which released: “INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Impax …” on November 08, 2016, also Businesswire.com with their article: “Glancy Prongay & Murray Commences Investigation on Behalf of Impax …” published on November 09, 2016, Prnewswire.com published: “EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims …” on November 04, 2016. More interesting news about Impax Laboratories Inc (NASDAQ:IPXL) were released by: Benzinga.com and their article: “Mid-Afternoon Market Update: Dow Climbs 250 Points; Impax Labs Shares Down …” published on November 09, 2016 as well as Businesswire.com‘s news article titled: “SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Impax …” with publication date: November 07, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.